Any clinician can readily measure blood pressure and serum levels of potassium and creatinine, and overdose-induced hypotension, hyperkalaemia, or hypercreatininaemia are easily corrected by reducing ...

Unique Characteristics of Hypertension in Blacks That Influence BP Responses to Drugs That Block the Renin-Angiotensin Activating System (RAAS) Blockade of the RAAS in Blacks for Cardiovascular and ...

In a study, patients who experienced hyperkalemia while on a renin-angiotensin-aldosterone-system inhibitor had the lowest 1-year risk of recurrent hyperkalemia when the medication was discontinued.

Evaluated renin-angiotensin-aldosterone system (RAAS) inhibitor drugs and their maximum doses, listed in descending order of observed frequency at index: lisinopril, 40 mg; losartan, 100 mg; valsartan ...

Please provide your email address to receive an email when new articles are posted on . Fewer patients with hyperkalemia were prescribed renin-angiotensin-aldosterone system inhibitors for HF.

At one time, dual RAAS blockade was expected to provide more-complete inhibition of RAAS among patients with DKD. Results of large clinical trials dashed these hopes, finding increased risk of AKI and ...

WASHINGTON -- Use of the potassium-binding agent patiromer (Veltassa) allowed more heart failure patients at risk for hyperkalemia to remain on optimal therapy with renin-angiotensin-aldosterone ...

Please provide your email address to receive an email when new articles are posted on . Renin-angiotensin-aldosterone system inhibitor use in patients with hypertension and intracranial aneurysm was ...

In a recent study posted to the medRxiv* preprint server, researchers conducted an umbrella review and meta-analysis of the renin-angiotensin-aldosterone system (RAAS) inhibitors' impact on ...

Combined capital will support the ongoing Phase 2a clinical trial of procizumab in cardiogenic shockSeries C round was supported by both existing ...

A woman reaching for a prescription bottle in a medicine cabinet Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia. Discontinuation of renin–angiotensin-aldosterone ...